Concentration of ondansetron in cerebrospinal fluid following oral dosing in volunteers

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Psychopharmacology

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/BF02247730PMID 1365869
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Determination of ondansetron in plasma and its pharmacokinetics in the young and elderly.

  1991cited by this paper
• A single-blind comparison of intravenous ondansetron, a selective serotonin antagonist, with intravenous metoclopramide in the prevention of nausea and vomiting associated with high-dose cisplatin chemotherapy.

  1991cited by this paper
• The determination in plasma and pharmacokinetics of ondansetron.

  1989cited by this paper

• Evaluation of the Cardiovascular and Serotonergic Modulatory Effects of Ondansetron in Healthy Dogs Under Anesthesia.

  2026cites this paper
• Differential effects of antiemetic serotonin receptor antagonist Ondansetron on nausea associated with CHRM3 rs2165870 and TACR1 rs3755468 single-nucleotide polymorphisms

  2025cites this paper
• Randomized Controlled Trial of the Effects of High-Dose Ondansetron on Clinical Symptoms and Brain Connectivity in Obsessive-Compulsive and Tic Disorders.

  2025cites this paper
• Ondansetron to reduce neonatal opioid withdrawal severity a randomized clinical trial

  2022cites this paper
• Optimizing a therapy for opiate use disorders: Characterizing ondansetron pharmacokinetics in blood and brain

  2022cites this paper
• The Physiological Control of Eating: Signals, Neurons, and Networks.

  2021cites this paper
• 5-HT3 Antagonist Ondansetron Increases apoE Secretion by Modulating the LXR-ABCA1 Pathway

  2019cites this paper
• Biowaiver Monograph for Immediate-Release Solid Oral Dosage Forms: Ondansetron.

  2019cites this paper
• Modality selective roles of pro-nociceptive spinal 5-HT2A and 5-HT3 receptors in normal and neuropathic states

  2018cites this paper
• Reply to Dr Peltz.

  2018cites this paper
• A Flawed Design Produces Flawed Results.

  2018cites this paper
• A Flawed Design Produces Flawed Results

  2018influential citation
• Design and evaluation of buccal films as paediatric dosage form for transmucosal delivery of ondansetron.

  2016cites this paper
• Low protein diets produce divergent effects on energy balance

  2016cites this paper
• Serotonin controlling feeding and satiety.

  2015cites this paper
• A Randomized Double-Blind, Double-Dummy, Multicenter Trial of Azasetron versus Ondansetron to Evaluate Efficacy and Safety in the Prevention of Delayed Nausea and Vomiting Induced by Chemotherapy

  2014cites this paper
• Ondansetron attenuates the activity of excitatory amino acid transporter type 3 expressed in Xenopus oocytes.

  2014cites this paper
• benzylpiperazin-1-yl) (3-methoxyquinoxalin-2-yl)methanone (6g) in Acute and Chronic Animal Models of Depression

  2013cites this paper
• 2-(4-substituted piperazin-1-yl)-1,8-naphthyridine-3-carboxylic acids: novel 5-HT3 receptor antagonists with anxiolytic-like activity in rodent behavioral models.

  2013cites this paper
• Eficácia da ondansetrona no tratamento de dependentes de álcool

  2013cites this paper
• 2-Amino-6-chloro-3,4-dihydroquinazoline: A novel 5-HT3 receptor antagonist with antidepressant character.

  2013cites this paper
• Anti-depressant like activity of N-n-butyl-3-methoxyquinoxaline-2-carboxamide (6o) a 5-HT3 receptor antagonist.

  2013cites this paper
• 5-HT3 receptor antagonists protect against pressure overload-induced cardiac hypertrophy in murine

  2012cites this paper
• Granisetron Adjunct to Fluvoxamine for Moderate to Severe Obsessive-Compulsive Disorder

  2012cites this paper
• Ondansetron Reverses Antihypersensitivity from Clonidine in Rats after Peripheral Nerve Injury: Role of &ggr;-Aminobutyric Acid in &agr;2-Adrenoceptor and 5-HT3 Serotonin Receptor Analgesia

  2012cites this paper
• Ondansetron Reverses Antihypersensitivity from Clonidine in Rats after Peripheral Nerve Injury Role of (cid:1) -Aminobutyric Acid in (cid:2) 2-Adrenoceptor and 5-HT3 Serotonin Receptor Analgesia

  2012cites this paper
• Antidepressant Potential of 5-HT3 Receptor Antagonist, N-n- propyl-3-ethoxyquinoxaline-2-carboxamide (6n)

  2012cites this paper
• In vivo assessment of antiemetic drugs and mechanism of lycorine-induced nausea and emesis

  2011cites this paper
• Ondansetron, a 5HT3-antagonist, Does Not Alter Dynamic Mechanical Allodynia or Spontaneous Ongoing Pain in Peripheral Neuropathy

  2011cites this paper
• 5-HT(3) receptors: role in disease and target of drugs.

  2010cites this paper
• Ondansetron and fluoxetine reduce sleep apnea in mice lacking monoamine oxidase A.

  2009influential citation
• Effect of central administration of ondansetron, a 5‐hydroxytryptamine‐3 receptor antagonist on gastric and duodenal ulcers

  2009cites this paper
• Unusual reactions to 5‐HT3 receptor antagonists in a child with rhabdomyosarcoma

  2009cites this paper
• Antidepressant-like effects of serotonin type-3 antagonist, ondansetron: an investigation in behaviour-based rodent models

  2008cites this paper
• Ondansetron Given Intravenously Attenuates Arterial Blood Pressure Drop Due to Spinal Anesthesia: A Double‐Blind, Placebo‐Controlled Study

  2008cites this paper
• Ondansetron Given Intravenously Attenuates Arterial Blood Pressure Drop Due to Spinal Anesthesia: A Double-Blind, Placebo-Controlled Study

  2008cites this paper
• Effects of ondansetron on the activity of glutamate transporter type 3 and the modulation mechanism Effects of nicotine on the activity of glutamate transporter type 3 and the modulation mechanism

  2008cites this paper
• De-stabilization of the positive vago-vagal reflex in bulimia nervosa.

  2008cites this paper
• On the function endogenous pain controlling systems in healthy subjects and patients with peripheral or central neuropathic pain

  2008cites this paper
• Efficacy of Mirtazapine in Obstructive Sleep Apnea Syndrome

  2007cites this paper
• Intestinal nutrients elicit satiation through concomitant activation of CCK(1) and 5-HT(3) receptors.

  2007cites this paper
• Serotonin-type 3 receptors mediate intestinal lipid-induced satiation and Fos-like immunoreactivity in the dorsal hindbrain.

  2007cites this paper
• Efficacy of mirtazapine in obstructive sleep apnea syndrome.

  2007cites this paper
• Evidence for a vagal pathophysiology for bulimia nervosa and the accompanying depressive symptoms.

  2006cites this paper
• Gastric distension enhances CCK-induced Fos-like immunoreactivity in the dorsal hindbrain by activating 5-HT3 receptors.

  2006cites this paper
• Serotonin type-3 receptors mediate cholecystokinin-induced satiation through gastric distension.

  2006cites this paper
• Dorsal hindbrain 5-HT3 receptors participate in control of meal size and mediate CCK-induced satiation.

  2006cites this paper
• Do 5HT3 Antagonists Antinociceptive Have an Effect

  2005cites this paper
• Cerebrospinal Fluid and Plasma Pharmacokinetics of the Cyclooxygenase 2 Inhibitor Rofecoxib in Humans: Single and Multiple Oral Drug Administration

  2005cites this paper
• CCK and 5-HT act synergistically to suppress food intake through simultaneous activation of CCK-1 and 5-HT3 receptors.

  2005cites this paper
• The 5HT3 Receptor Antagonist Ondansetron Can Have an Analgesic Effect in Chronic Human Neuropathic Pain

  2005cites this paper
• Serotonin-type 3 receptors mediate intestinal Polycose- and glucose-induced suppression of intake.

  2005cites this paper
• Cholecystokinin-induced satiety is mediated through interdependent cooperation of CCK-A and 5-HT3 receptors.

  2004cites this paper
• Pilot trial of ondansetron in the treatment of 8 patients with obsessive-compulsive disorder.

  2003cites this paper
• Lack of effect of 5HT3 antagonist in mediating subjective and behavioral responses to cotinine.

  2003cites this paper
• Does a Single Intravenous Injection of the 5HT3 Receptor Antagonist Ondansetron Have an Analgesic Effect in Neuropathic Pain? A Double-Blinded, Placebo-Controlled Cross-Over Study

  2003cites this paper
• Ondansetron attenuates CCK induced satiety and c-fos labeling in the dorsal medulla.

  2001cites this paper
• Oral serotonin type 3-receptor antagonists for prevention of chemotherapy-induced emesis.

  2000cites this paper
• Effect of decreasing afferent vagal activity with ondansetron on symptoms of bulimia nervosa: a randomised, double-blind trial.

  2000cites this paper
• Serotonin 5-HT3-receptor antagonist GR 38032F suppresses sleep apneas in rats.

  1998cites this paper
• Effect of ondansetron, a 5‐HT3 receptor antagonist, on the dynamic association between bulimic behaviors and pain thresholds

  1998cites this paper
• 5-HT3 receptor antagonism by ondansetron does not attenuate prolactin response to d-fenfluramine challenge in healthy human subjects.

  1996cites this paper
• Ondansetron. A review of its pharmacology and preliminary clinical findings in novel applications.

  1996cites this paper
• Clinical Pharmacokinetics of Ondansetron. A Review

  1996cites this paper
• 5-HT3 receptor antagonism by ondansetron does not attenuate prolactin response tod-fenfluramine challenge in healthy human subjects

  1996cites this paper
• Ondansetron Clinical Pharmacokinetics

  1995cites this paper